SCHEMBL858829

SCHEMBL858829

CNS(=O)(=O)c1cc(-c2ccc3c(c2)CN(c2ncnc(C)c2Cc2ccc(F)cc2)CCO3)cnc1N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 1/20 0.38
PIK3C3 Q8NEB9 2/20 0.36
PIK3CA P42336 6/20 0.35
PIK3CD O00329 2/20 0.34
PI4KA P42356 1/20 0.34
PIK3CG P48736 1/20 0.34
GPR142 Q7Z601 1/20 0.34
RPS6KB1 P23443 2/20 0.33
AURKA O14965 1/20 0.33
FLT1 P17948 1/20 0.33
GCK P35557 1/20 0.33
FLT4 P35916 1/20 0.33
MAP3K11 Q16584 1/20 0.33
STK17A Q9UEE5 1/20 0.33
TNIK Q9UKE5 1/20 0.33
RIPK2 O43353 1/20 0.32
NOD2 Q9HC29 1/20 0.32
AKT1 P31749 1/20 0.32
MTOR P42345 1/20 0.32
RIPK1 Q13546 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL859239 0.88 RPS6KB1 (0.36) PRKDCPIK3CAGPR142RPS6KB1AURKA
SCHEMBL856184 0.86 PIK3CA (0.38) PRKDCPIK3CAPIK3CDGPR142RPS6KB1
SCHEMBL858790 0.85 PRKDC (0.34) PRKDCPIK3CAGPR142RPS6KB1AURKA
SCHEMBL3802990 0.85 PRKDC (0.44) PRKDCPIK3CAPIK3CDGPR142RPS6KB1
SCHEMBL856296 0.81 GRIA1 (0.34) PRKDCPIK3CAGPR142RPS6KB1AURKA
SCHEMBL855967 0.81 PRKDC (0.33) PRKDCPIK3CAPIK3CDPIK3CGGPR142
SCHEMBL7860978 0.81 PRKDC (0.33) PRKDCPIK3CAPIK3CDPIK3CGGPR142
SCHEMBL858299 0.81 RPS6KB1 (0.36) PRKDCPIK3CAGPR142RPS6KB1AURKA
SCHEMBL858637 0.81 GPR142 (0.41) PRKDCPIK3CAGPR142RIPK1
SCHEMBL3755389 0.80 GRM5 (0.39) PRKDCPIK3CARPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US claimed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PRKDC 2737/4885PIK3C3 68/4885PIK3CA 3/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PRKDC 2431/4885PIK3C3 43/4885PIK3CA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.